Protica Bio

Company Overview

Snapshot

Founded in December 2021 by Olga Nissan, Protica Bio operates with 1–10 employees. The company has secured funding across one round from VLX Ventures. Protica Bio is developing an immunotherapy-based diagnostics platform, leveraging proteomics and machine learning to enhance clinical decisions and drug discovery.

Business overview

Protica Bio is dedicated to improving immunotherapy outcomes and accelerating new drug discoveries through its proprietary platform. The company combines advanced proteomics with machine learning to develop diagnostic capabilities, aiming to increase response rates for current and future treatments. It serves the health tech and life sciences sectors, specifically focusing on pharma and medical biotechnology, drugs discovery and development, and test diagnostics and screening.

Company Intelligence Q&A

When was Protica Bio founded?

Protica Bio was founded in December 2021 by Olga Nissan.

What is Protica Bio's primary focus?

Protica Bio focuses on combining proteomics and machine learning to improve immunotherapy-based clinical decisions and new drug discoveries, aiming to create diagnostic capabilities and elevate treatment response rates.

What technology does Protica Bio utilize?

Protica Bio utilizes a proprietary platform developed by an expert in mass spectrometry from the Weizmann Institute, integrating deep proteomics with machine learning.

What markets does Protica Bio serve?

Protica Bio operates within the health tech and life sciences sectors, with a focus on pharma and medical biotechnology, drugs discovery and development, and test diagnostics and screening.